Regulatory

Ascelia Pharma publishes Annual Report for the financial year 2018/2019

2019-10-14
Report

Ascelia Pharma’s Annual Report for the financial year 2018/2019 has today been published on the company’s website www.ascelia.com

For further information, please contact:
Mikael Widell, Head of IR & Communications
Email: mw@ascelia.com
Tel: +46 703 11 99 60

The information was submitted for publication, through the agency of the contact person set out above, at 6.00 p.m. CET on 14 October 2019.

2020-01-13

Five sites now opened in the pivotal Phase III clinical study SPARKLE for lead drug candidate Mangoral

Ascelia Pharma AB (publ) (ticker: ACE) today informed that there are a number of sites now open for enrolment of patients in both the US and Europe in the global pivotal Phase III clinical study SPARKLE with Mangoral[®]. Enrolment of the first patient is expected shortly.
2019-12-18

Nomination Committee appointed for AGM 2020 in Ascelia Pharma AB

Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 6 May 2020 has been appointed
2019-12-06

Ascelia Pharma appoints Julie Waras Brogren as Chief Commercial Officer

Ascelia Pharma AB (publ) (ticker: ACE) today announced that Julie Waras Brogren has been appointed as Chief Commercial Officer (CCO) of Ascelia Pharma. Julie will be a member of the Executive Management and will start in the beginning of January 2020.